The application of mesoporous silica nanoparticles as a drug delivery vehicle in oral disease treatment

Abstract

Mesoporous silica nanoparticles (MSNs) hold promise as safer and more effective medication delivery vehicles for treating oral disorders. As the drug’s delivery system, MSNs adapt to effectively combine with a variety of medications to get over systemic toxicity and low solubility issues. MSNs, which operate as a common nanoplatform for the co-delivery of several compounds, increase therapy effectiveness and show promise in the fight against antibiotic resistance. MSNs offer a noninvasive and biocompatible platform for delivery that produces long-acting release by responding to minute stimuli in the cellular environmen. MSN-based drug delivery systems for the treatment of periodontitis, cancer, dentin hypersensitivity, and dental cavities have recently been developed as a result of recent unparalleled advancements. The applications of MSNs to be embellished by oral therapeutic agents in stomatology are discussed in this paper.

Nanoparticle-Based Drug Delivery Systems for Enhancing Bone Regeneration

“…Although MSN have great potential for the targeted delivery of therapeutic factors, the oxidative stress and cell apoptosis still need to be addressed. Moreover, due to the inability of MSN carriers to achieve complete release, the therapeutic effect will be limited, which affects the evaluation of drug treatment effectiveness …”

Breaking barriers: The potential of nanosystems in antituberculosis therapy

“…The focus on the nanometric diameter and versatility of the MSNs have led to the exploration of a wide range of applications in the biomedical field including cancer treatment [ 330 , 331 ], infectious diseases [ 332 ], bone diseases [ 333 , 334 ], etc.…”

PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy

“…For example, MSN has a highly porous structure, which can provide a larger specific surface area to increase the contact area between ATO and water, and the functional groups modified on the surface can form complexes with ATO to improve the solubility. 21 MSN can slowly release ATO and prolong the half-life of the ATO in vivo , thus improving the bioavailability of the ATO and optimizing its pharmacokinetic characteristics. In addition, MSN can also improve the stability of ATO by protecting it from oxidation or degradation.…”